Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TYPHIBEV

Phase 2Biologic

TYPHIBEV is one of 19 biologic programs targeting Typhoid Fever. It is currently in Phase 2.

2

Indications

3

Total Trials

2

Active Trials

18

Competitors

Pipeline

Status by Indication[3][1]

Indication

Typhoid FeverActive, not recruiting

ShigellosisActive, not recruiting

Typhoid FeverPhase 2

Active, not recruiting

ShigellosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Typhoid Fever

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Merrem

BB. Braun Medical Inc.

Rocephin

CConrado Roberto Hoffmann Filho

Hepatitis a Vaccine

Cipro

Oral Cholera Vaccine

Levaquin

Gsk's Investigational Vaccine 692342

Typhoid Vi Vaccine

IInternational Vaccine Institute

Low Dose of Ints-TCV

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Typhoid Fever

NCT07286370

Q4 2028

Phase 2Not yet recruiting

Immunogenicity

NCT07320716

Clinical

Trials by Indication[1]

Typhoid Fever1 trial

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

Not yet recruiting· GSK logo

GSK·Phase 2·NCT07286370·537 enrolled

Immunogenicity1 trial

Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children

Not yet recruiting· GSK logo

GSK·Phase 2·NCT07320716·528 enrolled

Shigellosis1 trial

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

Completed· GSK logo

GSK·Phase 2·NCT06663436·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TYPHIBEV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TYPHIBEV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TYPHIBEV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: GSK

Related News